Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03583697 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia
A Phase 2 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT03583697 is a Phase 2 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 75 participants.
The verdict
NCT03583697, a Phase 2 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.
Interventions
- DRUG Placebo
- DRUG BMN 111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2022-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03583697
The ClinicalTrials.gov registry entry for NCT03583697 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03583697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03583697 about?
NCT03583697 is a clinical study titled "A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia". Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of achondroplasia.
What is the current status of trial NCT03583697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2018-06-13. Estimated completion is 2022-01-26.
What interventions are being tested in trial NCT03583697?
The interventions under investigation include: Placebo (DRUG), BMN 111 (DRUG).
Who is sponsoring clinical trial NCT03583697?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.